The Expansion of Comprehensive Genomic Profiling Into Earlier Disease Stages

This segment examines how comprehensive genomic profiling is now being used earlier in the lung cancer disease course. Dr Singhal explains that broader testing at diagnosis allows clinicians to rapidly identify patients who are eligible for targeted therapies, clinical trials, or biomarker driven treatment strategies. The panel notes that earlier access to molecular data shortens the time between diagnosis and appropriate therapy, which can be critical for patient outcomes. They also describe how the growing availability of large NGS panels has made this approach more practical in everyday care. This shift is changing workflow in both academic and community settings, making genomic testing a routine part of initial evaluation rather than a later step. The discussion highlights how this evolution is helping more patients receive precise therapy sooner.